**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 68811

**Manuscript Type:** CASE REPORT

**Aggressive natural killer cell leukemia with skin manifestation associated with hemophagocytic lymphohistiocytosis: a case report**

Peng XH *et al*. Aggressive natural killer cell Leukemia

Xiao-Huan Peng, Lian-Sheng Zhang, Li-Juan Li, Xiao-Jia Guo, Yang Liu

**Xiao-Huan Peng, Lian-Sheng Zhang, Li-Juan Li, Xiao-Jia Guo, Yang Liu,** Department of Hematology, Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Province, China

**Author contributions:** All authors were involved in drafting, reviewing and revising the manuscript and gave intellectual inputs.

**Corresponding author: Lian-Sheng Zhang, DPhil, Research Scientist,** Department of Hematology, Second Hospital of Lanzhou University, No. 82 Cuiyingmen, Lanzhou 730030, Gansu Province, China. zhanglsh@leu.edu.cn

**Received:** June 6, 2021

**Revised:** July 7, 2021

**Accepted:** August 23, 2021

**Published online:** December 6, 2021

**Abstract**

***BACKGROUND***

Aggressive natural killer cell leukemia (ANKL) is a rare natural killer cell neoplasm characterized by systemic infiltration of Epstein–Barr virus and rapidly progressive clinical course. ANKL can be accompanied with hemophagocytic lymphohistiocytosis (HLH). Here, we report a case of ANKL with rare skin lesions as an earlier manifestation, accompanied with HLH, and review the literature in terms of etiology, clinical manifestation, diagnosis and treatment.

***CASE SUMMARY***

A 30-year-old woman from Northwest China presented with the clinical characteristics of jaundice, fever, erythema, splenomegaly, progressive hemocytopenia, liver failure, quantities of abnormal cells in bone marrow, and associated HLH. The immunophenotypes of abnormal cells were positive for CD2, cCD3, CD7, CD56, CD38 and negative for sCD3, CD8 and CD117. The diagnosis of ANKL complicated with HLH was confirmed. Following the initial diagnosis and supplementary treatment, the patient received chemotherapy with VDLP regimen (vincristine, daunorubicin, L-asparaginase and prednisone). However, the patient had severe adverse reactions and complication such as severe hematochezia, neutropenia, and multiple organ dysfunction syndrome, and died a few days later.

***CONCLUSION***

This is the first reported case of ANKL with rare skin lesions as an earlier manifestation and associated with HLH.

**Key Words:** Aggressive natural killer cell leukemia; Hemophagocytic lymphohistiocytosis; Rare skin lesions; Epstein–Barr virus; Diagnosis and treatment; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Peng XH, Zhang LS, Li LJ, Guo XJ, Liu Y. Aggressive natural killer cell leukemia with skin manifestation associated with hemophagocytic lymphohistiocytosis: a case report. *World J Clin Cases* 2021; 9(34): 10708-10714

URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10708.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10708

**Core Tip:** Aggressive natural killer cell leukemia (ANKL) is a rare natural killer (NK) cell neoplasm characterized by systemic infiltration of Epstein–Barr virus and rapid development. Diagnosis and treatment of ANKL can be challenging due to its rapid development, rare nature, and varied clinical manifestations. Extranodal nasal NK/T cell leukemia, indolent NK cell lymphoproliferative disease, and T-large granular lymphoblastic leukemia must be considered in differential diagnosis. Standard therapy for ANKL has not been established because of its rare nature, rapid development, and poor prognosis. This is the first reported case of ANKL associated with hemophagocytic lymphohistiocytosis and rare skin lesions simultaneously.

**INTRODUCTION**

Aggressive natural killer cell leukemia (ANKL) is a rare mature natural killer (NK) cell malignant lymphoproliferative disease associated with Epstein–Barr virus (EBV) infection[1]. In general, patients with ANKL present with systemic symptoms, pancytopenia and hepatosplenomegaly. The skin lesion as an earlier manifestation of ANKL is very rare. ANKL runs an aggressive course and is usually rapidly fatal, with a median survival of only 2 mo[2].Only early diagnosis, active control of complications, prevention of further deterioration of the disease, and effective chemotherapy can win time for the survival of patients. We report the case of a 30-year-old that was diagnosed as ANKL associated with hemophagocytic lymphohistiocytosis (HLH).

**CASE PRESENTATION**

***Chief complaints***

A 30-year-old female patient presented to our Department of Hematology Medicine complaining of fatigue, abdominal distension for 1 mo, and yellow staining of skin and scattered erythema for 10 d.

***History of present illness***

She had been treated with antibiotics and Chinese patent drug for 3 d for a cold before admission to our hospital. However, the symptoms were not significantly improved. Abdominal distension became more serious with nausea and vomiting, then yellow staining and dense flaky erythema appeared across the whole body skin, mucous membranes and sclera. She was presented to our hospital.

***History of past illness***

There was no history of past illness.

***Personal and family history***

She and her family had no specific disease history. Both parents and one older brother were in good health.

***Physical examination***

Physical examination revealed that the whole skin, mucous membranes and sclera were yellow stained, and dense flaky erythema with scattered bleeding spots of different sizes were found on the forehead, behind the ears, neck and chest (Figure 1A), and the liver and spleen were obviously enlarged.

***Laboratory examinations***

The blood cell counts were as follows: hemoglobin (HGB) 97 g/L, platelets (PLTs) 15 × 109/L and leukocytes 22.92 × 109/L. Biochemical tests showed marked increased level of total bilirubin to 250.6 μmol/L, direct bilirubin to 221.6 μmol/L, alanine transaminase to 270 U/L, aspartate transaminase to 341 U/L, lactate dehydrogenase to 8527 U/L, and marked decreased level of the total protein to 53.1 g/L. The laboratory findings also found coagulopathy [high level of D-dimer (1.51 μg/mL) and fibrinogen degradation product (5.70 μg/mL)]. Bone marrow aspiration showed that cells with unknown classification and abnormality were easy to see, accounting for 94% (Figure 2A). Bone marrow biopsy test showed that hematopoietic tissue proliferation was heterogeneous, granulocyte and erythrocytic proliferation were decreased, megakaryocytic hyperplasia (0–4/high-power field) was scattered (Figure 2B). Immunohistochemistry of bone marrow biopsy showed that these atypical cells were positive for cCD3, CD20, CD34, CD68, CD56, CD2, CD7, and negative for sCD3 (Figure 2C). Serological tests for EBV revealed that EBV DNA was 7.22  106 copies. Multicolor flow cytometry revealed that abnormal cell populations of 90% were seen in areas where CD45 was strongly positive, expressing HLA-DR, CD2, CD7, CD38 and cCD3, and partially expressing CD56. Abnormal NK cells could be seen in the samples, considering the possible source of NK/T cells. *TCR* gene rearrangement test was negative.

***Imaging examinations***

Positron emission tomography (PET)/computed tomography (CT) of the whole body showed that metabolism was increased in multiple parts (Figure 1B). PET/CT revealed that malignant tumor cells of the lymphoid hematopoietic system accumulated in multiple organs.

**FINAL DIAGNOSIS**

According to the clinical manifestation, laboratory and imaging examination, the patient was diagnosed with ANKLassociated with HLH[3].

**TREATMENT**

Following the initial diagnosis and supplementary treatment of malignant tumors, such as transfusion of gammaglobulin, HGB, plasma and PLTs, the patient underwent chemotherapy with VDLP regimen (vincristine, daunorubicin, L-asparaginase and prednisone).

**OUTCOME AND FOLLOW-UP**

The patient had severe stomachache and vomiting on the second day of chemotherapy, and symptomatic support treatment such as proton pump inhibitor and antiemetic was given. On the third day of chemotherapy, severe hematochezia occurred. Blood pressure began to decrease; heart rate increased to 180 beats/min, HGB, and leukocyte and PLT counts were extremely low, especially PLTs. Considering ANKL complicated with HLH, neutropenia, myelosuppression, multiple organ dysfunction syndrome (MODS), the patient was transferred to the intensive care unit. The general condition of the patient did not improve and deteriorated. Finally, the patient died a few days later.

**DISCUSSION**

ANKL is a rare entity with < 200 cases published to date,and is always associated with EBV infection[1]. In 1986, Suzuki *et al*[4] put forward the concept of ANKL for the first time.In 2001, the World Health Organization classified it as ANKL in the classification of lymphoid tissue tumors, and extranodal NK/T cell lymphoma and extranodal nasal NK/TX cell leukemia (ENKTCL) were both mature NK cell tumors[5]. With the emergence of the next generation of sequencing technology, the molecular basis of ANKL has been clarified. In recent years, the introduction of combined chemotherapy including L-asparaginase (L-ASP),and allogeneic hematopoietic cell transplantation, has helped some patients achieve complete remission and potential cure in theory[6]. However, the prognosis of ANKL is still poor, with a median survival time of 2 mo[7].

ANKL is a systemic disease; the main clinical symptoms are obvious B symptoms, including high fever, fatigue, night sweats, loss of appetite, weight loss, jaundice, and hepatosplenomegaly[8]. The blood cell counts are mostly one-line or multi-line progressive decrease, and the activity of serum lactate dehydrogenase and FASL levels are often high[9]. ANKL is often associated with HLH. Compared with ENKTCL, skin damage is rare[8]. The course of the disease is outbreak, usually accompanied by diffuse intravascular coagulation, leading to multiple organ failure, which progresses to death within a few weeks.

At present, there are no unified diagnostic criteria for ANKL and the more recognized diagnostic criteria are: (1) more immature large granular leukocytes in peripheral blood and bone marrow; (2) rapidly progressive B symptoms, liver, spleen and lymph node enlargement, neutropenia, low HGB, thrombocytopenia, liver function and blood coagulation abnormalities; (3) EBV antibody or DNA positive; (4) immunophenotype conforms to CD2+ CD56+ sCD3− TCRαβ− TCRγδ−; (5) common chromosomal abnormalities del; and (6) q21q25[10]. The genetic changes of ANKL are largely unknown, which is in sharp contrast to the rich genetic information of ENKTCL; a disease closely related to ANKL. Some gene mutations in ANKL, including the JAK–STAT and Ras–MAPK systems, are found in the signal transduction system. Some studies have shown that the frequent mutations in the JAK–STAT signaling system are STAT3 or STAT5B. *STAT3* represents the most frequently mutated gene (~20% of cases)[11]. Tumor suppressor genes *TP53* and *DDX3X*, epigenetic modification genes *CREBBP*, *TET2*, *MLL2*, *BCOR* and *SETD2* and hypermethylation mutation of *HACE1* have also been described in ANKL[12]. However, in terms of clinical practice, the diagnosis of ANKL still depends to a large extent on leukemic cells with abnormal morphology and immunophenotype. Chromosome gain and loss, *STAT3* and *STAT5B* mutations, and *HACE1* hypermethylation were detected only in sporadic cases.

HLH is also a rare hematological disease, but it is one of the common complications of ANKL. In one published study, there were 34 patients with ANKL, of which 19 (56%) developed HLH during the course of treatment[13]. It was secondary HLH because it was secondary to NK cell leukemia.

Initially, a large area of dense flaky erythema with scattered bleeding spots of different sizes appeared on the forehead, behind the ears, neck and chest. We found no relevant reports in the literature. It has been reported that skin lesions in ANKL are relatively rare compared with ENKTCL[7], but skin lesions were found in the present case. The patient died due to rapid progression of the disease; therefore, we lost the opportunity to clarify the nature of the skin lesions and their relationship with the primary disease. The systemic invasion of tumor cells in this patient was obvious, so it can be speculated that the condition was complicated with rare skin lesions.

At present, there are no unified clinical treatment standards or prospective clinical trials specifically for ANKL. The widely accepted clinical chemotherapy regimens are: CHOP-like regimen (including anthracycline and vincristine), L-ASP + methotrexate + dexamethasone regimen, SMILE (dexamethasone + methotrexate + ifosfamide + L-ASP + VP16) regimen, and acute lymphoblastic leukemia intensive chemotherapy (VDLP) regimen[10]. Some studies have shown that the high expression of P-glycoprotein encoded by multidrug resistance gene *MDR1* in NK tumor cells may be related to the poor response of ANKL to chemotherapy and relapse after chemotherapy[14]. Most studies have shown that antineoplastic drugs whose action mechanism was not affected by P-glycoprotein, such as L-ASP, had an effect on ANKL, especially in high-risk patients[15]. The chemotherapy regimens based on MTX, L-ASP and VP16, such as SMILE, have shown promising results[16]. Allogeneic hematopoietic stem cell transplantation after remission is the main method to improve the prognosis of ANKL patients.

In the present case of ANKL complicated with HLH, disease progression was rapid. According to current research, it was suggested that SMILE or L-ASP + methotrexate + dexamethasone regimen should be used to control the primary disease, but considering the poor condition of the patient, she could not tolerate the adverse reactions of SMILE intensive therapy. Finally, VDLP regimen was used. Unfortunately, the patient had severe abdominal pain with vomiting in the course of chemotherapy, serious hematochezia occurred on the third day of chemotherapy, and blood pressure dropped rapidly. The patient died a few days later.

**CONCLUSION**

ANKL is still a challenging disease due to its rapid development, rare nature, and variety of clinical manifestations. Therefore, only early diagnosis, active control of complications, prevention of further deterioration of the disease, and effective chemotherapy can win time for the survival of patients.

**ACKNOWLEDGMENTS**

We are thankful to the family of the patient for permitting us to use their case for presentation.

**REFERENCES**

1 **Lima M**. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. *Orphanet J Rare Dis* 2013; **8**: 95 [PMID: 23816348 DOI: 10.1186/1750-1172-8-95]

2 **Suzuki R**, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K; NK-cell Tumor Study Group. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. *Ann Oncol* 2010; **21**: 1032-1040 [PMID: 19850638 DOI: 10.1093/annonc/mdp418]

3 **Henter JI**, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2007; **48**: 124-131 [PMID: 16937360 DOI: [10.1002/pbc.21039](https://doi.org/10.1002/pbc.21039)]

4 **Suzuki R**, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S, Gondo H, Hino N, Mori H, Sugimori H, Kawa K, Oshimi K; NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. *Leukemia* 2004; **18**: 763-770 [PMID: 14961041 DOI: 10.1038/sj.leu.2403262]

5 **Chan JK**. The new World Health Organization classification of lymphomas: the past, the present and the future. *Hematol Oncol* 2001; **19**: 129-150 [PMID: 11754390 DOI: 10.1002/hon.660]

6 **Ishida F**, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, Nakamura S, Suzuki R. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. *Cancer Sci* 2012; **103**: 1079-1083 [PMID: 22360679 DOI: 10.1111/j.1349-7006.2012.02251.x]

7 **Gill H**, Liang RH, Tse E. Extranodal natural-killer/t-cell lymphoma, nasal type. *Adv Hematol* 2010; **2010**: 627401 [PMID: 21234094 DOI: 10.1155/2010/627401]

8 **Gao LM**, Zhao S, Liu WP, Zhang WY, Li GD, Küçük C, Hu XZ, Chan WC, Tang Y, Ding WS, Yan JQ, Yao WQ, Wang JC. Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites. *Am J Surg Pathol* 2016; **40**: 836-846 [PMID: 26975038 DOI: 10.1097/PAS.0000000000000634]

9 **Tse E**, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. *J Hematol Oncol* 2017; **10**: 85 [PMID: 28410601 DOI: 10.1186/s13045-017-0452-9]

10 **Ishida F**, Kwong YL. Diagnosis and management of natural killer-cell malignancies. *Expert Rev Hematol* 2010; **3**: 593-602 [PMID: 21083476 DOI: 10.1586/ehm.10.51]

11 **Huang L**, Liu D, Wang N, Ling S, Tang Y, Wu J, Hao L, Luo H, Hu X, Sheng L, Zhu L, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou K, Cao L, Dong L, Zheng X, Sui P, He J, Mo S, Yan J, Ao Q, Qiu L, Zhou H, Liu Q, Zhang H, Li J, Jin J, Fu L, Zhao W, Chen J, Du X, Qing G, Liu H, Liu X, Huang G, Ma D, Zhou J, Wang QF. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. *Cell Res* 2018; **28**: 172-186 [PMID: 29148541 DOI: 10.1038/cr.2017.146]

12 **Nakashima Y**, Tagawa H, Suzuki R, Karnan S, Karube K, Ohshima K, Muta K, Nawata H, Morishima Y, Nakamura S, Seto M. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/Leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. *Genes Chromosomes Cancer* 2005; **44**: 247-255 [PMID: 16049916 DOI: 10.1002/gcc.20245]

13 **Nicolae A**, Ganapathi KA, Pham TH, Xi L, Torres-Cabala CA, Nanaji NM, Zha HD, Fan Z, Irwin S, Pittaluga S, Raffeld M, Jaffe ES. EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. *Am J Surg Pathol* 2017; **41**: 67-74 [PMID: 27631517 DOI: 10.1097/PAS.0000000000000735]

14 **Jaccard A**, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. *Blood* 2011; **117**: 1834-1839 [PMID: 21123825 DOI: 10.1182/blood-2010-09-307454]

15 **Ando M**, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K. Selective apoptosis of natural killer-cell tumours by l-asparaginase. *Br J Haematol* 2005; **130**: 860-868 [PMID: 16156856 DOI: 10.1111/j.1365-2141.2005.05694.x]

16 **Kwong YL**, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. *Blood* 2012; **120**: 2973-2980 [PMID: 22919026 DOI: 10.1182/blood-2012-05-431460]

**Footnotes**

**Informed consent statement:** This study was approved by the Ethics Committee of Lanzhou University Second Hospital and got the consent and support from patient’s family before the writing.

**Conflict-of-interest statement:** All authors declared that they have no potential conflicts of interest to report.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review started:** June 6, 2021

**First decision:** June 25, 2021

**Article in press:** August 23, 2021

**Specialty type:** Hematology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Azmi AS **S-Editor:** Wu YXJ **L-Editor:** Kerr C **P-Editor:**Guo X

**Figure Legends**



**Figure 1 Physical examination and positron emission tomography/computed tomography scan (PET/CT).** A: The forehead, behind the ears, neck and chest had dense flaky erythema with scattered bleeding spots of different sizes; B: PET/CT showed that metabolism was obviously increased in the right nasal cavity, right maxillary sinus, right frontal sinus, partial ethmoid sinus, bilateral sphenoid sinus, right turbinate, nasopharynx, uterus, tail of pancreas, bilateral breast, multiple lymph nodes, liver and spleen, and bone marrow.



**Figure 2 Hematoxylin–eosin staining.** A: Bone marrow cell morphology test showed that cells with unknown classification and abnormality were easy to see, accounting for 94% (magnification: 4 × 10 and 10 × 10); B: Bone marrow biopsy test showed that hematopoietic tissue proliferation was heterogeneous, adipose tissue hyperplasia was decreased, granulocyte and erythrocytic proliferation was decreased, megakaryocytic hyperplasia (0–4/high-power field) was scattered (magnification: 10 × 10 and 10 × 40); C: Immunohistochemical of bone marrow biopsy showed that the atypical cells were positive for CD2, cCD3, CD7, CD20, CD34, CD68, CD56, and negative for sCD3 (magnification: 10 × 10; 10 × 40 and 10 × 10).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**